Integrated BioPharma reports FY net income $8.0M, revenue up 20.5% YoY

INTEGRATED BIOPHARMA INC

Revenue for FY ended June 30, 2021: $63.6M, up 20.5% YoY from $52.8M.
FY net income $8.0M ($0.27 basic EPS) vs $4.1M ($0.14 basic EPS) prior year.
Q4 revenue $17.1M (+26.7% YoY); Q4 net income $4.5M ($0.15 basic EPS) vs $1.9M ($0.06).
FY operating income $5.8M vs $3.3M prior year; PPP forgiveness of $1.7M boosted other income.
Two customers represent ~92% of total revenue in both FY2021 and FY2020, per co-CEOs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.